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A series of thieno[2,3-d]- and thieno[3,2-d]pyrimidines have been easily synthesized using as key 
step a deproto-cadmiation-trapping sequence. Some of the compounds thus synthesized were 
screened for anti-cancer (cytotoxic) activities, and (S)-2-(6-iodo-2-phenylthieno[2,3-d]pyrimidin-10 
4-ylamino)-3-phenylpropanoic acid proved to have a significant activity towards liver, human 
breast and cervix carcinoma cell lines. 
Introduction 
Thienopyrimidine derivatives, which are structural analogues 
of purines, have been drawn attention due to their large range 15 
of pharmacological activities.1 Numerous thieno[2,3-
d]pyrimidines have been proved to be phosphodiesterase 
inhibitors and various receptor antagonists; compounds were 
designed to act as immunomodulators or to be used in case of 
cerebral ischemia, malaria, tuberculosis, Alzheimer’s and 20 
Parkinson’s diseases.1 Many thieno[2,3-d]- and thieno[3,2-
d]pyrimidines exhibit antitumor and radioprotective 
activities.1 
 Lithium bases have been largely employed for the deproto-
metallation of aromatic rings.2 Nevertheless, for aromatics 25 
bearing reactive functions (e.g., ester or cyano groups) or 
sensitive π-deficient heterocycles, either extremely low 
reaction temperatures or in situ electrophilic trapping are 
required due to the high reactivity of the corresponding 
(hetero)aryllithiums. 30 
 The use of metal additives in order to get more efficient or 
more chemoselective bases is a challenging field, and various 
RnMLi type compounds already prepared behave as 
superbases since such species exhibit behaviours that cannot 
be reproduced by the monometallic compounds on their own. 35 
Among them, the RnMLi mixtures of organolithiums and M 
alkali metal alkoxides described by Schlosser,3 Lochmann,4 
and Caubère5 are powerful reagents. 
 More recently, RnMLi type compounds with M different 
from an alkali metal have also been described for their 40 
unprecedented metallation ability. These species display a 
large panel of reactivities, depending on both the metal M and 
the groups connected to it.6 By combining soft organometallic 
compounds with lithium additives, bases allowing both 
efficient and chemoselective reactions have been prepared and 45 
used to generate functionalized aromatic compounds.7 
 We recently accomplished the deproto-metallation of a 
large range of aromatics including heterocycles using a newly 
developed lithium-cadmium base, (TMP)3CdLi (TMP = 
2,2,6,6-tetramethylpiperidino),8 and we here describe its use 50 
for the functionalization of thieno[2,3-d]- and thieno[3,2-
d]pyrimidines. Some intermediates and target compounds 
were evaluated for their cytotoxic activity. 
Results and discussions 
Synthetic aspects 55 
To this purpose, 4-chlorothieno[2,3-d]pyrimidine (1) was 
synthesized as described recently under microwave 
irradiation.9 4-Chloro-2-phenylthieno[3,2-d]pyrimidine (2) 
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Scheme 1 Synthesis of the substrates 1-7. 
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was prepared (as shown in Scheme 1) from commercially 
available methyl 3-aminothiophene-2-carboxylate by adapting 
a described procedure.10 Isomeric 4-chloro-2-
phenylthieno[2,3-d]pyrimidine (3) was similarly synthesized, 
but from known 2-aminothiophene-3-carboxamide.11 Starting 5 
from 4-chlorothieno[2,3-d]pyrimidine (1), a subsequent 
functionalization at the 4 position was easily achieved either 
by nucleophilic substitution using sodium methoxide to afford 
the ether 4, or by copper-catalyzed N-arylation of pyrazole by 
adapting described conditions12 to furnish the derivative 5. 4-10 
Chloro-2-phenylthieno[2,3-d]pyrimidine (3) was readily 
converted by reaction with sodium methoxide or morpholine 
to the compounds 6 and 7, respectively (Scheme 1). 
 In contrast to thiophene compounds which can be easily 
metallated using lithium bases,13 pyrimidines are much more 15 
prone to nucleophilic attacks,14 and their metallation can only 
be achieved at room temperature when softer bases are 
employed.8,15 The lithium-cadmium base (TMP)3CdLi was 
chosen for the metallation of the thienopyrimidine substrates 
because of its high compatibility with sensitive heterocycles.8 20 
 Conducting the reaction from 4-chloro- (1) and 4-
methoxythieno[2,3-d]pyrimidine (4) using 0.5 equivalent8 of 
base in tetrahydrofuran (THF) at room temperature for 2 h 
resulted, after quenching with iodine, in the formation of the 
iodides 8 and 9, respectively (48 and 90% yield). Unlike five-25 
membered heterocycles, for which protons adjacent to 
heteroatoms have the strongest acidity, six-membered 
heterocycles have the weakest acidic protons adjacent to 
nitrogens, a result of the more important repulsion between 
the lone electron pair of nitrogen and the negative charge of 30 
the carbanion for the latter, due to the smaller angle between 
the two electron clouds.16 As a consequence, the substrates 1 
and 4 are regioselectively deprotonated at the most acidic 6 
position (Table 1, entries 1,2). Upon treatment with 0.5 equiv 
of (TMP)3CdLi under the same reaction conditions, 4-35 
(pyrazol-1-yl)thieno[2,3-d]pyrimidine (5) did not undergo 
regioselective deprotonation, and only a mixture of several 
inseparable derivatives was obtained (Entry 3). Starting from 
4-chloro-2-phenylthieno[3,2-d]pyrimidine (2), metallation 
still took place next to the sulfur atom, as evidenced by 40 
trapping with iodine to afford the 6-iodo derivative 10a in 
70% yield (compound 10a was identified unequivocally by X-
ray structure analysis.).† Turning to 1 equivalent of base 
(instead of 0.5) allowed a slight yield improvement (76%) but 
also, more importantly, the formation of the diiodide 10b in 45 
18% yield. The latter could result from a dideprotonation due 
to the activation of the site at the 7 position by the close 
nitrogen atom (Entries 4,5). Isomeric 4-chloro-2-
phenylthieno[2,3-d]pyrimidine (3) was similarly 
functionalized in an excellent yield (Entry 6). By replacing 50 
the chloro group with a methoxy or a morpholino group17 
(substrates 6 and 7), the conditions were optimized, and the 
best yields were obtained using 1 equivalent of base (Entries 
7,8). 
 It also proved possible to trap the metallated 4-(morpholin-55 
4-yl)-2-phenylthieno[2,3-d]pyrimidine prepared from the 
substrate 7 in a palladium-catalyzed cross-coupling reaction 
with 2-bromopyridine. Indeed, by using catalytic amounts of 
palladium acetate and 1,1’-bis(diphenylphosphino)ferrocene 
(dppf), the expected product 14 was isolated in 70% yield 60 
(Scheme 2). 
Table 1 Deproto-cadmiation (using (TMP)3CdLi)-iodination. 
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a Metallation took place but not regioselectively, and the products formed 
could not be separated. 
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Scheme 3 Cytotoxic activity of 2-(6-iodo-2-phenylquinazolin-4-
ylamino)-3-phenylpropanoic acid. 
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 In order to progress towards molecules with potential anti-
tumor activities, we decided to prepare thiophene analogues of 
2-(6-iodo-2-phenylquinazolin-4-ylamino)-3-phenylpropanoic 
acid, which proved to exhibit anti-cancer activity (cytotoxic) 
against U937 leukemia cell lines (Scheme 3).18 5 
 
 To this purpose, different 2-phenyl-4-
chlorothienopyrimidines, iodinated or not, were involved in 
the nucleophilic substitution reaction of the chloride by L-
phenylalanine, under the conditions described in the 10 
quinazoline series18 to afford the analogues 15-19 (Table 2, 
entries 1-5). N-methyl-L-phenylalanine, L-phenylalaninol and 
L-proline were then used in order to evidence the importance 
of the secondary amine and carboxylic acid functions (entries 
6-8, compounds 20-22). 15 
Pharmacology 
The compounds 6, 7, 12-14, 16, 19, 20 and 21 were tested 
against a liver carcinoma cell line (HEPG2), a human breast 
carcinoma cell line (MCF7), and a cervix carcinoma cell line 
(HELA) (Table 3). The compounds 6, 7, 12, 14 and 16 20 
showed a low activity towards the liver carcinoma cell line 
HEPG2 compared to a reference drug (doxorubicin); the 
compounds 13, 20 and 21 showed a moderate activity whereas 
the compound 19 was found to have a very potent activity 
towards HEPG2 with a IC50 of 0.40 μg/mL (the IC50 value for 25 
the reference drug, doxorubicin, is 0.70 μg/mL). Concerning 
the activity towards the human breast carcinoma cell line 
MCF7, all the compounds showed moderate activities 
compared to the reference drug doxorubicin except the 
compound 19 which turned out to be promising. For the 30 
cervix carcinoma cell line HELA, all the compounds have low 
activities compared to the reference drug doxorubicin, except 
the compounds 6 and 19 which were found to be more 
effective towards this kind of carcinoma cell line (HELA) 
than other compounds. 35 
Conclusions 
A series of thieno[2,3-d]- and thieno[3,2-d]pyrimidines have 
been easily synthesized. The key step is a deprotonation-
trapping sequence using a mixed lithium-cadmium base. Most 
Table 2 Nucleophilic substitution of the 4-chlorothienopyrimidines by an 
amino acid or derivative. 
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Table 3a In vitro cytotoxic activity (IC50)
b of the newly synthesized 
compounds and doxorubicin against a liver carcinoma cell line (HEPG2), 
a human breast carcinoma cell line (MCF7), and a cervix carcinoma cell 
line (HELA).c 
 
Entry Compound HEPG2 (g/mL) MCF7 (g/mL) HELA (g/mL) 
1 6 3.4 1.6 2.8 
2 7 2.5 1.3 4.4 
3 12 2.6 2.1 3.5 
4 13 1.2 2.7 4.0 
5 14 4.3 2.2 4.7 
6 16 2.7 1.5 5.0 
7 19 0.40 0.94 1.3 
8 20 1.6 1.6 3.0 
9 21 1.7 2.4 5.6 
10 doxorubicin 0.60 0.70 0.85 
 
a The cadmium presence in the tested compounds was not evaluated since 
CdCl2·TMEDA was used at the last but one step, but in case of further 
development these compounds would have to be synthesized using a safe 
base and tested again. b IC50 is defined as the concentration which results 
in a 50% decrease in cell number as compared with that of the control 
structures in the absence of an inhibitor. c Pharmacological tests have also 
been performed for compounds 15, 17, 18 and 22, but they failed to give 
logical results. 
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of the compounds were screened in order to evidence an anti-
cancer activity. Some of them such as (S)-2-(6-iodo-2-
phenylthieno[2,3-d]pyrimidin-4-ylamino)-3-phenylpropanoic 
acid (19) showed significant cytotoxic activities towards the 
tested cell lines, in particular with the liver and human breast 5 
carcinoma cell lines. 
Experimental 
Syntheses: general methods 
Metallation reactions were performed under argon atmosphere. 
THF was distilled over sodium/benzophenone. Column 10 
chromatography separations were achieved on silica gel (40–63 
m). Melting points were measured on a Kofler apparatus. 1H and 
13C Nuclear Magnetic Resonance (NMR) spectra were recorded 
on a Bruker ARX-200 spectrometer at 200 and 50 MHz, 
respectively, on a Bruker Avance III spectrometer at 300 and 75 15 
MHz, respectively, or on a Bruker AC-400 spectrometer at 300 
and 75 MHz, respectively. 1H chemical shifts () are given in 
ppm relative to the solvent residual peak, and 13C chemical shifts 
relative to the central peak of the solvent signal.19 Mass spectra 
(HRMS) measurements were performed at the CRMPO (Centre 20 
Régional de Mesures Physiques de l’Ouest) of Rennes using 
either a Waters Q-TOF 2 or a Bruker micrOTOF Q II instrument 
in positive or negative elestrospray CI mode, respectively, or a 
Micromass MS/MS ZABSpec TOF instrument in EI mode. 
Elemental analyses were performed at the CRMPO using a 25 
Thermo-Finnigan Flash EA 1112 CHNS analyzer. 
 4-Chlorothieno[2,3-d]pyrimidine (1)9 and 2-aminothiophene-
3-carboxamide11 were prepared according to described 
procedures. 2-Benzoylaminothiophene-3-carboxamide and 2-
phenyl-3H-thieno[2,3-d]pyrimidin-4-one20 were prepared by 30 
adapting a described procedure.10 
Methyl 3-benzoylaminothiophene-2-carboxylate was prepared 
by adapting a described procedure.10 To a mixture of methyl 3-
aminothiophene-2-carboxylate (2.2 g, 14 mmol) and Et3N (2.4 
mL, 17 mmol) in CH2Cl2 (18 mL) at 0°C was added dropwise 35 
benzoyl chloride (2.0 mL, 17 mmol). After stirring at room 
temperature for 3 h, the reaction mixture was diluted with CH2Cl2 
and washed with saturated NaHCO3 and brine. The organic layer 
was dried over Na2SO4 and concentrated under reduced pressure. 
The resulting solid was purified by column chromatography on 40 
silica gel (eluent: heptane/Et2O 96:4 to 80:20) to give methyl 3-
benzoylaminothiophene-2-carboxylate (3.7 g, 98%) as a white 
solid: mp 98°C (lit.21 98-99°C). 
2-Phenyl-3H-thieno[3,2-d]pyrimidin-4-one22 was prepared by 
adapting a described procedure.10 To a solution of methyl 3-45 
benzoylaminothiophene-2-carboxylate (2.0 g, 7.6 mmol) in 
MeOH (80 mL) was added a 25% aqueous NH3 solution (200 
mL). After stirring at 50°C for 17 h, the reaction mixture was 
concentrated to one-half of its initial volume and the resulting 
solid was collected to give a mixture of 3-benzoylamino-50 
thiophene-2-carboxamide and 2-phenyl-3H-thieno[3,2-
d]pyrimidin-4-one (0.84 g). To this mixture in MeOH (34 mL) 
was added a 2 N aqueous NaOH solution (12 mL). After stirring 
at reflux for 17 h, the reaction mixture was acidified with 1 M 
HCl until pH 4 and the resulting precipitate was collected to give 55 
2-phenyl-3H-thieno[3,2-d]pyrimidin-4-one (0.80 g, 46%) as a 
white solid: mp > 260°C. HRMS: calcd for C12H8N2OS (M
+) 
228.0357, found 228.0348. 
4-Chloro-2-phenylthieno[3,2-d]pyrimidine (2)22 was prepared 
by adapting a described procedure.10 A mixture of 2-phenyl-3H-60 
thieno[3,2-d]pyrimidin-4-one (1.6 g, 7.0 mmol) and POCl3 (16 
mL, 0.17 mol) was heated at reflux for 4 h. POCl3 was then 
distilled under reduced pressure. The residue was diluted in 
CH2Cl2, and neutralized with a cooled saturated NaHCO3 
solution. The aqueous layer was extracted with CH2Cl2 and the 65 
combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated. The resulting solid was purified by 
column chromatography on silica gel (eluent: heptane/CH2Cl2 
100:0 to 0:100) to give 2 (1.5 g, 90%) as a white solid: mp 118-
119°C. Anal. Calcd for C12H7N2ClS: C, 58.42; H, 2.86; N, 11.35; 70 
S, 13.00. Found: C, 58.08; H, 3.00; N, 11.28; S, 12.98%. 
4-Chloro-2-phenylthieno[2,3-d]pyrimidine (3) was prepared as 
before but starting from 2-phenyl-3H-thieno[2,3-d]pyrimidin-4-
one (1.6 g), and was obtained after recrystallization from AcOEt 
in a quantitative yield as a white solid: mp 148°C (lit.23 146°C). 75 
4-Methoxythieno[2,3-d]pyrimidine (4)24 To a solution of 
MeONa in MeOH (0.18 g, 8.0 mmol of Na in 40 mL of MeOH) 
was added 4-chlorothieno[2,3-d]pyrimidine (1, 0.68 g, 4.0 
mmol). After stirring at reflux for 1.5 h, the reaction mixture was 
quenched with water, extracted with CH2Cl2, dried over Na2SO4 80 
and concentrated. The resulting solid was purified by column 
chromatography on silica gel (eluent: heptane/AcOEt 70:30) to 
give 4 (0.45 g, 67%) as a white solid: mp 51°C. Anal. Calcd for 
C7H6N2OS: C, 50.59; H, 3.64; N, 16.86; S, 19.29. Found: C, 
50.89; H, 3.73; N, 16.46; S, 19.21%. 85 
4-Methoxy-2-phenylthieno[2,3-d]pyrimidine (6) was prepared 
as before from 4-chloro-2-phenylthieno[2,3-d]pyrimidine (3, 0.98 
g). Column chromatography on silica gel (eluent: CH2Cl2/heptane 
50:50) afforded 6 (2.1 g, 91%) as a pale yellow solid: mp 90-
92°C. Anal. Calcd for C13H10N2OS: C, 64.44; H, 4.16; N, 11.56; 90 
S, 13.23. Found: C, 64.53; H, 4.26; N, 11.36; S, 12.74%. 
4-(Pyrazol-1-yl)thieno[2,3-d]pyrimidine (5) was prepared from 
4-chlorothieno[2,3-d]pyrimidine (1, 0.68 g) by adapting a 
described procedure.25 Purification by column chromatography 
on silica gel (eluent: heptane/Et2O 80:20) afforded 5 (0.61 g, 95 
75%) as a white solid: mp 115°C. Anal. Calcd for C9H6N4S: C, 
53.45; H, 2.99; N, 27.70; S, 15.86. Found: C, 53.77; H, 2.99; N, 
27.52; S, 15.77%. 
4-(Morpholin-4-yl)-2-phenylthieno[2,3-d]pyrimidine (7). To a 
solution of morpholine (0.38 g, 4.4 mmol) and 4-chloro-2-100 
phenylthieno[2,3-d]pyrimidine (3, 1.0 g, 4.0 mmol) in dry toluene 
(25 mL) was added K2CO3 (1.1 g, 8.0 mmol). After stirring at 
reflux for 1 h, one more equivalent of morpholine was added 
(0.35 g, 4.0 mmol). The mixture was stirred again for 2 h at 
reflux, filtered through celite
®
, and the filtrate was concentrated 105 
under reduced pressure. The resulting solid was purified by 
column chromatography on silica gel (eluent: CH2Cl2) to give 7 
(1.0 g, 89%) as a yellow solid: mp 140°C (lit.23 139°C). Anal. 
Calcd for C16H15N3OS: C, 64.62; H, 5.08; N, 14.13; S, 10.78. 
Found: C, 64.79; H, 5.15; N, 14.08; S, 10.43%. 110 
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General procedure for the deproto-cadmiation (using 0.5 
equiv (TMP)3CdLi)-iodination. To a stirred, cooled (0°C) 
solution of 2,2,6,6-tetramethylpiperidine (0.25 mL, 1.5 mmol) in 
THF (5 mL) was added BuLi (about 1.6 M hexanes solution, 1.5 
mmol). After 15 min at 0°C, CdCl2·TMEDA (0.15 g, 0.5 mmol) 5 
was added, and the mixture was stirred for 15 min at this 
temperature before introduction of the substrate (1.0 mmol). After 
2 h at room temperature, a solution of I2 (0.37 g, 1.5 mmol) in 
THF (5 mL) was added. The mixture was stirred overnight before 
addition of an aqueous saturated solution of Na2S2O3 (10 mL) and 10 
extraction with Et2O (3 x 20 mL). The combined organic layers 
were washed with brine (20 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure before purification by 
column chromatography on silica gel (the eluent is given in the 
product description). 15 
4-Chloro-6-iodothieno[2,3-d]pyrimidine (8) was prepared from 
4-chlorothieno[2,3-d]pyrimidine (1, 0.17 g) following the general 
procedure. After purification by column chromatography on silica 
gel (eluent: CH2Cl2), compound 8 was obtained as a white solid 
(0.14 g, 48%): mp 168°C. Anal. Calcd for C6H2ClIN2S: C, 24.30; 20 
H, 0.68; N, 9.45; S, 10.81. Found: C, 24.68; H, 1.06; N, 9.12; S, 
10.73%. 
6-Iodo-4-methoxythieno[2,3-d]pyrimidine (9) was prepared 
from 4-methoxythieno[2,3-d]pyrimidine (4, 0.17 g) following the 
general procedure. After purification by column chromatography 25 
on silica gel (eluent: heptane/AcOEt 90:10), compound 9 was 
obtained as a white solid (0.26 g, 90%): mp 152°C. Anal. Calcd 
for C7H5IN2OS: C, 28.78; H, 1.73; N, 9.59; S, 10.98. Found: C, 
29.09; H, 1.82; N, 9.43; S, 11.43%. 
4-Chloro-6-iodo-2-phenylthieno[3,2-d]pyrimidine (10a) was 30 
prepared from 4-chloro-2-phenylthieno[3,2-d]pyrimidine (2, 0.25 
g) following the general procedure. After purification by column 
chromatography on silica gel (eluent: heptane/CH2Cl2 98:2 to 
74:26), compound 10a was obtained as a white solid (0.26 g, 
70%): mp 138°C. Anal. Calcd for C12H6ClIN2S: C, 38.68; H, 35 
1.62; N, 7.52; S, 8.61. Found: C, 38.69; H, 1.73; N, 7.71; S, 
8.32%. 
4-Chloro-6-iodo-2-phenylthieno[2,3-d]pyrimidine (11) was 
prepared from 4-chloro-2-phenylthieno[2,3-d]pyrimidine (3, 0.25 
g) following the general procedure. After purification by column 40 
chromatography on silica gel (eluent: CH2Cl2/heptane 50:50), 
compound 11 was obtained as a white solid (0.36 g, 97%): mp 
148°C. Anal. Calcd for C12H6ClIN2S: C, 38.68; H, 1.62; N, 7.52; 
S, 8.61. Found: C, 39.01; H, 1.92; N, 7.37; S, 8.70%. 
General procedure for the deproto-cadmiation (using 1 equiv 45 
(TMP)3CdLi)-iodination. To a stirred, cooled (0°C) solution of 
2,2,6,6-tetramethylpiperidine (0.25 mL, 1.5 mmol) in THF (5 
mL) was added BuLi (about 1.6 M hexanes solution, 1.5 mmol). 
After 15 min at 0°C, CdCl2·TMEDA (0.15 g, 0.5 mmol) was 
added, and the mixture was stirred for 15 min at this temperature 50 
before introduction of the substrate (0.5 mmol). After 2 h at room 
temperature, a solution of I2 (0.37 g, 1.5 mmol) in THF (5 mL) 
was added. The mixture was stirred overnight before addition of 
an aqueous saturated solution of Na2S2O3 (10 mL) and extraction 
with Et2O (3 x 20 mL). The combined organic layers were 55 
washed with brine (20 mL), dried over Na2SO4, filtered, and 
concentrated under reduced pressure before purification by 
column chromatography on silica gel (the eluent is given in the 
product description). 
4-Chloro-6,7-diiodo-2-phenylthieno[3,2-d]pyrimidine (10b) 60 
was prepared from 4-chloro-2-phenylthieno[3,2-d]pyrimidine (2, 
0.12 g) following the general procedure. After purification by 
column chromatography on silica gel (eluent: heptane/CH2Cl2 
98:2 to 74:26), compound 10b was obtained as a white solid (45 
mg, 18%): mp 176°C. Anal. Calcd for C12H5ClI2N2S: C, 28.91; 65 
H, 1.01; N, 5.62; S, 6.43. Found: C, 33.23; H, 2.12; N, 5.21; S, 
6.13% (partial loss of iodine was observed upon storage). Note 
that compound 10a was also obtained in 76% yield. 
6-Iodo-4-methoxy-2-phenylthieno[2,3-d]pyrimidine (12) was 
prepared from 4-methoxy-2-phenylthieno[2,3-d]pyrimidine (6, 70 
0.12 g) following the general procedure. After purification by 
column chromatography on silica gel (eluent: CH2Cl2/heptane 
50:50), compound 12 was obtained as a white solid (0.15 g, 
81%): mp 144-146°C. Anal. Calcd for C13H9IN2OS: C, 42.41; H, 
2.46; N, 7.61; S, 8.71. Found: C, 42.44; H, 2.42; N, 7.95; S, 75 
8.43%. 
6-Iodo-4-(morpholin-4-yl)-2-phenylthieno[2,3-d]pyrimidine 
(13) was prepared from 4-(morpholin-4-yl)-2-phenylthieno[2,3-
d]pyrimidine (7, 0.15 g) following the general procedure. After 
purification by column chromatography on silica gel (eluent: 80 
CH2Cl2), compound 13 was obtained as a yellow solid (0.18 g, 
83%): mp 206-208°C. Anal. Calcd for C16H14IN3OS: C, 45.40; H, 
3.33; N, 9.93; S, 7.85. Found: C, 45.11; H, 3.46; N, 9.57; S, 
7.36%. 
4-(Morpholin-4-yl)-2-phenyl-6-(pyridin-2-yl)-thieno[2,3-85 
d]pyrimidine (14). To a stirred, cooled (0°C) solution of 2,2,6,6-
tetramethylpiperidine (0.26 mL, 1.5 mmol) in THF (2 mL) was 
added BuLi (about 1.6 M hexanes solution, 1.5 mmol). After 15 
min at 0°C, CdCl2·TMEDA (0.15 g, 0.5 mmol) was added, and 
the mixture was stirred for 15 min at this temperature before 90 
introduction of 4-(morpholin-4-yl)-2-phenylthieno[2,3-
d]pyrimidine (7, 0.15 g, 0.5 mmol). After 2 h at room 
temperature, Pd(OAc)2 (3.4 mg, 15 mol), 1,1’-
bis(diphenylphosphinoferrocene) (9 mg, 15 mol) and 2-
bromopyridine (0.48 mL, 0.5 mmol) were added successively, 95 
and the mixture was heated at reflux overnight. The mixture was 
filtered through celite
®
, and the cake was washed with CH2Cl2. 
After purification by column chromatography on silica gel 
(eluent: CH2Cl2/AcOEt 100:0 to 90:10), and crystallization from 
acetonitrile, compound 14 was obtained as a yellow solid (0.13 g, 100 
70%): mp > 260°C. HRMS: calcd for C21H19N4OS ([M+H]
+) 
375.1280, found 375.1282. 
General procedure for the nucleophilic substitution of 4-
chlorothienopyrimidines by an amino acid or derivative. A 
previously described procedure was adapted.18 A mixture of the 105 
required 4-chlorothienopyrimidine (0.13 mmol) and amino acid 
or derivative (0.14 mmol), and potassium carbonate (0.59 mmol) 
in DMSO (0.6 mL) was heated overnight at 100°C. After cooling 
to room temperature, 1N HCl was added until pH 4. The resulting 
solid was collected and purified by column chromatography on 110 
silica gel (AcOEt/MeOH 80:20). 
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(S)-3-Phenyl-2-(2-phenylthieno[3,2-d]pyrimidin-4-
ylamino)propanoic acid (15) was prepared from 4-chloro-2-
phenylthieno[3,2-d]pyrimidine (2, 32 mg) and using L-
phenylalanine (23 mg) following the general procedure, and was 
obtained as a pale yellow solid (32 mg, 66%): mp > 240°C. 5 
HRMS: calcd for C21H16N3O2S ([M-H]
-
) 374.0969, found 
374.0971. 
(S)-2-(6-Iodo-2-phenylthieno[3,2-d]pyrimidin-4-ylamino)-3-
phenylpropanoic acid (16) was prepared from 4-chloro-6-iodo-
2-phenylthieno[3,2-d]pyrimidine (10a, 48 mg) and using L-10 
phenylalanine (23 mg) following the general procedure, and was 
obtained as a pale yellow solid (36 mg, 55%): mp > 240°C. 
HRMS: calcd for C21H15IN3O2S ([M-H]
-
) 499.9935, found 
499.9947. 
(S)-2-(6,7-Diiodo-2-phenylthieno[3,2-d]pyrimidin-4-ylamino)-15 
3-phenylpropanoic acid (17) was prepared from 4-chloro-6,7-
diiodo-2-phenylthieno[3,2-d]pyrimidine (10b, 65 mg) and using 
L-phenylalanine (23 mg) following the general procedure, and 
was obtained as a pale yellow solid (39 mg, 48%): mp > 240°C. 
HRMS: calcd for C21H14I2N3O2S ([M-H]
-
) 625.8902, found 20 
625.8916. 
(S)-3-Phenyl-2-(2-phenylthieno[2,3-d]pyrimidin-4-
ylamino)propanoic acid (18) was prepared from 4-chloro-2-
phenylthieno[2,3-d]pyrimidine (3, 32 mg) and using L-
phenylalanine (23 mg) following the general procedure, and was 25 
obtained as a pale yellow solid (31 mg, 53%): mp > 240°C. 
HRMS: calcd for C21H16N3O2S ([M-H]
-
) 374.0969, found 
374.0968. 
(S)-2-(6-Iodo-2-phenylthieno[2,3-d]pyrimidin-4-ylamino)-3-
phenylpropanoic acid (19) was prepared from 4-chloro-6-iodo-30 
2-phenylthieno[2,3-d]pyrimidine (11, 48 mg) and using L-
phenylalanine (23 mg) following the general procedure, and was 
obtained as a pale yellow solid (52 mg, 80%): mp > 240°C. 
HRMS: calcd for C21H17IN3O2S ([M+H]
+) 502.0086, found 
502.0088. 35 
(S)-2-[(6-Iodo-2-phenylthieno[2,3-d]pyrimidin-4-
yl)(methyl)amino]-3-phenylpropanoic acid (20) was prepared 
from 4-chloro-6-iodo-2-phenylthieno[2,3-d]pyrimidine (11, 48 
mg) and using N-methyl-L-phenylalanine (25 mg) following the 
general procedure, and was obtained as a pale yellow solid (50 40 
mg, 74%): mp > 240°C. HRMS: calcd for C22H17IN3O2S ([M-H]
-
) 514.0092, found 514.0085. 
(S)-2-(6-Iodo-2-phenylthieno[2,3-d]pyrimidin-4-ylamino)-3-
phenylpropan-1-ol (21) was prepared from 4-chloro-6-iodo-2-
phenylthieno[2,3-d]pyrimidine (11, 48 mg) and using L-45 
phenylalaninol (21 mg) following the general procedure, and was 
obtained as a pale yellow solid (25 mg, 40%): mp > 240°C. 
HRMS: calcd for C14H11IN3OS ([M-C7H7]
+) 395.9668, found: 
395.9626. 
(S)-1-(6-Iodo-2-phenylthieno[2,3-d]pyrimidin-4-50 
yl)pyrrolidine-2-carboxylic acid (22) was prepared from 4-
chloro-6-iodo-2-phenylthieno[2,3-d]pyrimidine (11, 48 mg) and 
using L-proline (16 mg) following the general procedure, and was 
obtained as a pale yellow solid (22 mg, 38%): mp > 240°C. 
HRMS: calcd for C16H14IN3S ([M-CO2]
+) 406.9953, found: 55 
406.9925. 
Pharmacology 
The method applied is similar to that reported by Skehan et al.26 
using 20 Sulfo-Rhodamine-B stain (SRB). Cells were plated in 
96-multiwell plate (104 cells/well) for 24 h before treatment with 60 
the test compound to allow attachment of cell to the wall of the 
plate. Different concentrations of the compound under test (0, 1.0, 
2.5, 5.0, and 10 μg/ml) were added to the cell monolayer in 
triplicate wells individual dose, and monolayer cells were 
incubated with the compounds for 48 h at 37oC and in 65 
atmosphere of 5% CO2. After 48 h, cells were fixed, washed and 
stained with SRB stain, excess stain was washed with acetic acid 
and attached stain was recovered with Tris-EDTA buffer. Color 
intensity was measured in an ELISA reader, and the relation 
between surviving fraction and drug concentration is plotted to 70 
get the survival curve of each tumor cell line after the specified 
compound and the IC50 was calculated. 
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A series of thieno[2,3-d]- and thieno[3,2-d]pyrimidines have been synthesized
using as key step a deproto-cadmiation-trapping sequence. One derivative
proved to have a significant activity towards the liver carcinoma cell line HEPG2.  
 
